1 / 14

Annual Report Johnson&Johnson

Annual Report Johnson&Johnson. Emily Cecil ACG2021 004. Executive Summary.

marly
Télécharger la présentation

Annual Report Johnson&Johnson

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Annual ReportJohnson&Johnson Emily Cecil ACG2021 004

  2. Executive Summary • Johnson & Johnson has become a worldwide leader in the field of health care. By year end 2005 the company reached a new sales record of $50.5 billion, a 7 percent increase form the year before. Johnson & Johnson has growing pharmaceutical and medical diagnostics braches that are continuing to expand. The Johnson & Johnson arms reach far beyond the consumer brands such as Johnson’s Baby, Tylenol, and Neutrogena that the public has come to know and respect. The company has plans to dive deeper in virology, in developing resistant strains against the HIV virus. The company is also developing new advances in cardiovascular health, and anti-psychotics. After an intensive review of the financial statements for 2005, it is clear that the company is also moving ahead financially. The cash flow increased to $11.9 billion, and thus Johnson & Johnson was able to increase its dividends to its share holders. Total assets and total stockholders equity increased while total liabilities decreased. Research and development expenses also increased. Johnson & Johnson has a commitment to new improvements in the health care field that will help to improve lives around the world. • Investor Relations - Annual Reports & Proxy

  3. Introduction • Chief Executive Officer : William C. Weldon Chairman, and Board of Directors • Location of home office: 1 Johnson & Johnson Plaza, New Brunswick, NJ 08933 • Johnson & Johnson is a worldwide leader in the manufacture of pharmaceuticals and health care products. The Johnson &Johnson family of corporations includes Neutrogena, Johnson’s Baby, Splenda, Tylenol, and countless others. The Medical and Diagnostics businesses are becoming an ever growing part of Johnson & Johnson and are committed to the prevention of disease as well as new medical and surgical improvements.

  4. Audit Report • Johnson & Johnson have a corporate staff of internal auditors who travel around the world monitoring the accounting system. Other independent auditors include the Pricewaterhouse Coopers LLP, who are an independent public accounting firm who perform an audit of the financial statements. • After reviewing the consolidated financial statements of Johnson & Johnson in accordance with the standards of the Public Company Accounting Oversight Board the auditors found that the financial statements accurately show the financial position of the company. The auditors also came to the conclusion that the companies internal control over financial reporting was also accurate and fair. • Report of Independent Registered Public Accounting available at http://www.jnj.com/2005AnnualReport/financials/independent/index.htm

  5. Security: JNJ Exchange: New York Stock Exchange Currency: US Dollars Most Recent Price of Stock: $64.75 Dividend per share: $.38 as of 8/25/06 Date of the above information: Oct. 10, 2006 As an investor, I would highly recommend buying and holding Johnson & Johnson stock as an investment. In 2005 Johnson & Johnson “increased [their] quarterly dividend to shareholders for the 43rd consecutive year ,..by nearly 16 percent to $.33 (Johnson & Johnson Annual Report p1). Stock Market Information

  6. Industry Situation and Company Plans • Johnson & Johnson was founded in 1886 and has become a worldwide leader in the manufacturing of pharmaceutical, medical devices, and consumer goods. The corporation is made of 230 subsidiary companies and operates in almost every company in the world. Some of the most well know consumer products include Band-Aid, Tylenol, Johnson’s Baby, Aveeno, Clean and Clear, Stayfree, and more. The pharmaceutical branch includes anti-infective, cardiovascular, neurology, psychotropic, hematology, as well as others. The primary focus and outlook of the industry has been to improve the future of health care around the world. In 2005 Johnson & Johnson “invested $6.3 billion in research and development, a $1.1 billion increase, or more than 21 percent above [the] 2004 investment (Johnson & Johnson Annual Report 2005). Expansions and “business building acquisitions” are also a large part of the future of the industry (Johnson & Johnson Annual Report 2005). In 2005 Johnson &Johnson acquired Animas, an insulin delivery corporation, as well as Hand Innovations LLC. A leader in the extremities market. The health care industry is growing and expanding everyday, and so is Johnson & Johnson. Their dedication to research and development and their promise to continue to improve health care for people around the world solidifies Johnson & Johnson as a successful and long standing industry. • Sources: www.marketwatch.comhttp://en.wikipedia.org/wiki/Johnson_&_Johnson Johnson&Johnson 2005 Annual Report

  7. Income Statement • The income statement from the 2005 Annual Report is in multi step format. • Gross Profit , Income from Operation, and Net Income all increased from 2004 to 2005. These increases were achieved through efforts in cost management and greater productivity.

  8. Balance Sheet • Important and impressive increases on the balance sheet include current assets, inventories, total current assets, property, plant, and equipment, accounts receivable, and total stockholders’ equity. Some of the note worthy decreases include total current liabilities, total liabilities, accounts payable, and long term debt. All of these movements helped Johnson & Johnson reach record high financial status in 2005 with a 7 percent growth rate of $50.5 billion.

  9. Statement of Cash Flows • Cash flows for the past two years have been more than net income. • Cash Flows: 2005-11,877 2004- 11,131 Net Income: 2005- 10, 411 2004- 8,509 • The company has been growing through acquisitions, investments and the purchasing of property, plant, and equipment. In 2005 Johnson & Johnson paid $2,632 billion in additions to property, plant, and equipment, $5,660 billion in investments, and $987 million in acquisitions. • Johnson & Johnson’s primary source of financing are short term loans. • Johnson & Johnson has seen an overall increase in cash from 2004 to 2005. The end of the year cash for 2004 was $9,203 billion followed by a substantial increase to $16,055 billion in 2005.

  10. Accounting Policies • Inventories: Inventories are stated at the at the lower of cost or market determined by the first in, first out method. • Revenue Recognition: The company recognizes revenue from product sales when the goods are shipped or delivered and title and risk of loss pass to the customer. • Property, Plant, and Equipment are stated at cost. • Short term marketable securities are carried at cost, which approximates fair value. • 1. Summary of Significant Accounting Policies 2. Inventories 3. Property, plant, and Equipment 4. Rental Expense and Lease Commitments 5. Employee Related Obligations 6. Borrowings 7. Intangible Assets and Goodwill 8. Income Taxes 9. International Currency Translation 10. Common Stock, Stock Option Plans, and Stock Compensation Agreements 11. Segments of Business and Geographic Areas 12. Accumulated other Comprehensive Income 13. Pensions and other Benefit Plans 14. Cash Equivalents and Marketable Securities 15. Financial Instruments 16. Savings Plan 17. Mergers, Acquisitions and Divestitures 18. Legal Proceedings 19. Earnings per share 20. Capital and Treasury Stock 21. Selected Quarterly Financial Data (unaudited) 22. Subsequent Events

  11. Financial Analysis Liquidity Ratios • Working Capital: 2005- 31,392-12,635= 18,759 2004- 27,320- 13,927= 13,393 • Current Ratio: 2005- 31,394/12,635= 2.5 2004- 27,320/13927= 1.9 • Receivable Turnover: 2005- 50,514/6920.5= 7.29 2004- 47348/6702.5=7.06 • Average days’ sales uncollected: 2005- 365/7.29= 50.07 2004- 365/7.06= 51.7 • Inventory Turnover: 2005- 13,954/3851.50= 3.62 2004- 13422/3666= 3.7 • Average days’ inventory on hand: 2005- 365/3.62= 100 2004- 365/3.7= 99.7

  12. Financial Analysis Profitability Ratios • Profit Margin: 2005- 10411/50514= 20.61% 2004- 8509/47348= 18% • Asset Turnover: 2005- 50514/55671= .91 2004- 47348/50790= .93 • Return on Assets: 2005- 10411/55671= 18.7% 2004- 8509/50790= 16.8% • Return on Equity: 2005- 10411/34842= 29.88% 2004- 8509/29341= 29%

  13. Financial Analysis Solvency Ratio • Debt to Equity: 2005- 20154/ 37871= .5 2004- 21504/ 31813= .68 • The debt to equity for 2005 was .5 meaning that the stockholders, rather than the creditors own the majority of the company.

  14. Financial Analysis Market Strength Ratios • Price/Earnings per share: 2005- 10411/2973.9= 3.50 2004- 8509/2968.4= 2.87 • Dividend Yield: 2005- 1.275/62.17= 2.05% 2004- 1.095/55.98= 1.96%

More Related